"Sofosbuvir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
| Descriptor ID |
D000069474
|
| MeSH Number(s) |
D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500
|
| Concept/Terms |
Sofosbuvir- Sofosbuvir
- 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester
PSI 7977- PSI 7977
- 7977, PSI
- PSI7977
- PSI-7977
|
Below are MeSH descriptors whose meaning is more general than "Sofosbuvir".
Below are MeSH descriptors whose meaning is more specific than "Sofosbuvir".
This graph shows the total number of publications written about "Sofosbuvir" by people in this website by year, and whether "Sofosbuvir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 6 | 7 |
| 2016 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sofosbuvir" by people in Profiles.
-
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
-
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 2019 12; 157(6):1506-1517.e1.
-
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328.
-
Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia. Am J Hematol. 2019 02; 94(2):E43-E45.
-
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
-
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
-
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
-
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
-
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
-
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.